Company DescriptionTrue North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.

Proceeds PurposesProceeds from the financing will be used to accelerate further development of its lead complement inhibitor, TNT009, for Cold Agglutinin Disease (CAD), as well as other rare diseases targeting the Complement system.